Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease - Wikidata - awgldk - TriplyDB

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease

http://www.wikidata.org/entity/Q35485586

about

Statins for the treatment of dementia Statins for the treatment of dementia Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.Cholesterol-modifying strategies for Alzheimer's disease.Atorvastatin therapy is associated with greater and faster cerebral hemodynamic response The effects of cholesterol on learning and memory.Cochrane review on 'Statins for the treatment of dementia'.Nutrition and prevention of Alzheimer's dementia.Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review.Contribution of vascular risk factors to the progression in Alzheimer disease Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans Cardiac risk factors and potential treatments in Alzheimer's disease.Dyslipidemia and the risk of Alzheimer's disease.Vascular risk factors, cognitive decline, and dementia Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment.Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers.Telephone interview for cognitive status: Creating a crosswalk with the Mini-Mental State Examination.Predictive Factors of Rapid Cognitive Decline in Patients with Alzheimer Disease.Rapid cognitive decline in Alzheimer's disease: a literature review.Impact on cognitive function-are all statins the same?Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease.Biochemical and Radiological Markers of Alzheimer's Disease Progression.Neurological consequences of obesity.Statin treatment affects cytokine release and phagocytic activity in primary cultured microglia through two separable mechanisms.Decreased serum lipids in patients with probable Alzheimer's disease.PPARs: a new target for neuroprotection.Interrelationship between Mini-Mental State Examination scores and biochemical parameters in patients with mild cognitive impairment and Alzheimer's disease.Leukocyte Telomere Length in Alzheimer's Disease Patients with a Different Rate of Progression.Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status.

P2860

Q24194901-72C6CA7D-A52D-4CE0-963B-6F666F884379 Q24236484-FC7BBA88-D96D-4B77-8BBE-4A4A48D5AC17 Q31047131-E3FEE109-C617-41FB-8F9C-AC330AC775DE Q33347051-49C98560-45D3-4CBC-8212-BAE175606655 Q33649943-074A278D-A885-433F-8FE9-AF4DF78317F3 Q33976829-1D308CDB-BA8C-47D4-97ED-481106FD5623 Q34219516-9381A114-7746-4052-BEE8-21F0DD914A3A Q34369234-33A6E539-4AF0-472F-BF96-C055C04AC975 Q34484520-9D242CE2-CE59-4725-AF63-2DC5E277769E Q35017596-75BE62DB-3B14-4A0E-BB41-8723618B6601 Q35642416-92EAD64D-C777-4AA8-9C9A-674513F0D89D Q35700985-2D73B5C0-B576-4DCE-ABB8-373FA8D80623 Q36226873-0422375F-A064-4B6D-BDD9-811722449543 Q36317839-C06D2C81-7017-4E3B-AEF6-7485DB81126D Q36351416-A9CDD0A9-5E39-4F63-ACF2-F4B275F44947 Q36582769-B7550B93-FD9A-4E2F-897F-D07F36285A25 Q36587136-BECC681B-DA54-4B16-972E-669DE0F305F6 Q36812802-B4A46840-E2AA-49E1-9CF9-EF70B734BED5 Q36822295-1B3F63B0-995A-43E3-A0B8-F6438F475D6E Q36959256-36BB947B-48A7-4811-B2D3-3F0E3D92B23B Q37171311-7718EB09-DA67-472F-A74E-0ED7F22EB750 Q37411298-D69757CC-7AAD-4FFA-BB86-E848E34D6422 Q37438471-111383F8-BA1A-4FF9-81BE-7EB77A14EA75 Q37562863-2EBE92D0-6F5A-438F-B685-69F6ABE113F4 Q38178371-FAF2C5AF-5293-4D36-835A-30C9A04F4537 Q38268341-2F206392-7E90-4323-81BD-DAF266785910 Q38672178-1057E380-D4BB-4CB3-8949-EEB371442A43 Q38693438-B1E0DE55-1455-4A8D-8DB8-1D1D2BC9A744 Q39306482-807F82BE-139D-49DA-B944-0AFE037A46AC Q41848796-71D5D5E2-191C-4F4E-BF6F-0097C94D2DF0 Q42270835-356C101A-3B05-4F62-92D4-58FC82E4463E Q42718625-25BC2FD6-7EEC-4B23-BFEF-2E83FCCEC6C5 Q47860207-50E37E99-7019-4787-AFAC-AAF5DC62E947 Q50563248-A656C4A8-C5F3-4CC3-88FD-08F8193404BF Q51896759-C2755585-1FC4-4F1D-9BB9-E30BD8A59748

P2860

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease

http://www.wikidata.org/entity/Q35485586

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Lipid lowering agents are asso ...... decline in Alzheimer's disease

@ast

Lipid lowering agents are asso ...... decline in Alzheimer's disease

@en

type

label

Lipid lowering agents are asso ...... decline in Alzheimer's disease

@ast

Lipid lowering agents are asso ...... decline in Alzheimer's disease

@en

prefLabel

Lipid lowering agents are asso ...... decline in Alzheimer's disease

@ast

Lipid lowering agents are asso ...... decline in Alzheimer's disease

@en

P1433

Q35485586-210A86F7-4AB7-41C4-B254-6EDC13C6506C

P1476

Q35485586-02864CC8-2C9B-4DA0-9D3E-F09D0D520D3A

P2093

Q35485586-512706D0-80AD-49C7-8D6A-C8D419A2C32D

Q35485586-A044D3B6-055E-4CE7-81A1-676DFF98E6D2

Q35485586-C406F8D9-1AEF-4805-8C05-BD19A8FE7855

Q35485586-CE2F4237-997D-4D1E-AFFF-41A14F642768

Q35485586-EA5FBFC0-2F01-4D3A-B8BC-80CADD2AA890

P2860

Q35485586-00626703-397E-4A06-9B11-7A4C4AF5264C

Q35485586-0135B273-E05A-4F74-83E2-C720DBF99C31

Q35485586-0B436A47-1DA2-48E7-851D-D1AF0CA97083

Q35485586-0C20EDF5-633F-4537-966C-141B0967D72E

Q35485586-0C57B0F8-122F-4667-B9B6-F4FF983EE10D

Q35485586-0D1F52D0-8F45-4079-9466-0FC091A6D89B

Q35485586-1181CA7A-7746-4CAF-9824-440F7043E449

Q35485586-17C881FD-A6FB-4AB5-87ED-A07D5C453112

Q35485586-1ED4E396-028C-4F61-BF18-FA575A0DAF44

Q35485586-21A93C27-2F33-415F-A807-C30BFE79DC30

P304

Q35485586-B5054663-8CFE-442B-B061-6EECE08634D7

P31

Q35485586-19C6CADE-570B-407D-8685-474A09DDB165

P356

Q35485586-F244B828-4462-4D1F-BBCC-2F1A6182C76F

P407

Q35485586-F04F3E18-4361-419C-B71D-7E92E92AC786

P433

Q35485586-1866B18A-0C0B-42CF-BB60-C0B9FF01B33E

P478

Q35485586-ECED9B0C-93C8-4771-9B14-847712459E05

P50

Q35485586-B3A3C27D-E8A7-460A-8F25-D7218D9B4D58

Q35485586-EDE9A36F-F4CA-4F48-951F-F2B1B34822D8

P577

Q35485586-F0D35331-3177-4EAB-9ED1-36ACC895E2AF

P5875

Q35485586-BE44F114-0B09-46FA-B58F-680B72827141

P698

Q35485586-5103BA02-E9AF-46CE-BB19-25868FD53BF9

P921

Q35485586-D68662AE-56AA-4BFC-8BCF-6994C221985C

P932

Q35485586-B1896F97-3FE7-4A12-B036-20A40FF42983

P356

JNNP.2005.063388

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Lipid lowering agents are asso ...... decline in Alzheimer's disease

@en

P2093

A Al Khedr

http://www.w3.org/2001/XMLSchema#string

C Libersa

http://www.w3.org/2001/XMLSchema#string

F Richard

http://www.w3.org/2001/XMLSchema#string

I Masse

http://www.w3.org/2001/XMLSchema#string

R Bordet

http://www.w3.org/2001/XMLSchema#string

P2860

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Alzheimer's disease: the cholesterol connection

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease.

The role of cholesterol in the biosynthesis of beta-amyloid.

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.

P304

1624-1629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.2005.063388

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Florence Pasquier

Dominique Deplanque

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7476429

http://www.w3.org/2001/XMLSchema#string

P698

16291883

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1739466

http://www.w3.org/2001/XMLSchema#string